Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 15, 2021
A DNA-Encoded Chemical Library Based on Peptide MacrocyclesYuichi Onda, Gabriele Bassi, Abdullah Elsayed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 19, 2022
A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor UptakeAndrea Galbiati, Aureliano Zana, Matilde Bocci, et al.
Cancer Immunology Research|April 21, 2026
Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors HotGudrun Thorhallsdottir, Ramon Benz, Pinuccia Faviana, et al.
Bioinformation|September 23, 2011
New inhibitors of VEGFR-2 targeting the extracellular domain dimerization processMohammad Amin Elgamacy, Raed Ahmed Shalaby, Ahmad Tawfik Elkodsh, et al.
Mabs|May 27, 2023
Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigenLouis Plüss, Frederik Peissert, Abdullah Elsayed, et al.
Molecular Cancer Therapeutics|September 30, 2025
Immunocompetent mouse models of cancer reveal the superiority of cellular targets over stromal targets for the development of anticancer bispecific antibodiesStefanie K Pfister, Frauke Seehusen, Francesco Prisco, et al.
Protein Science : a Publication of the Protein Society|November 1, 2022
Selection of a PD-1 blocking antibody from a novel fully human phage display libraryFrederik Peissert, Louis Plüss, Anna Maria Giudice, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2021
An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applicationsJacopo Millul, Gabriele Bassi, Jacqueline Mock, et al.
EMBO Molecular Medicine|March 6, 2024
A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitorsGiulia Rotta, Ettore Gilardoni, Domenico Ravazza, et al.
Mabs|June 8, 2023
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation propertiesAbdullah Elsayed, Christian Pellegrino, Louis Plüss, et al.
Pageof 2